Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Juan-Jose Lahuerta"'
Autor:
Adrian Mosquera Orgueira, Marta Sonia González Pérez, Jose Diaz Arias, Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Joaquin Martinez Lopez, Luis Palomera, Miguel Granell, Maria Jesus Blanchard, Javier de la Rubia, Ana López de la Guia, Rafael Rios, Anna Sureda, Miguel Teodoro Hernandez, Enrique Bengoechea, María José Calasanz, Norma Gutierrez, Maria Luis Martin, Joan Blade, Juan-Jose Lahuerta, Jesús San Miguel, Maria Victoria Mateos, the PETHEMA/GEM Cooperative Group
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-9 (2022)
Abstract The International Staging System (ISS) and the Revised International Staging System (R-ISS) are commonly used prognostic scores in multiple myeloma (MM). These methods have significant gaps, particularly among intermediate-risk groups. The a
Externí odkaz:
https://doaj.org/article/cddc86ce994b44c6bfb5da1a17d16eaf
Autor:
Maria-Teresa Cedena, Estela Martin-Clavero, Sandy Wong, Nina Shah, Natasha Bahri, Rafael Alonso, Carmen Barcenas, Antonio Valeri, Johny Salazar Tabares, Jose Sanchez-Pina, Clara Cuellar, Thomas Martin, Jeffrey Wolf, Juan-Jose Lahuerta, Joaquin Martinez-Lopez
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237155 (2020)
BackgroundStringent complete response (sCR) is used as a deeper response category than complete response (CR) in multiple myeloma (MM) but may be of limited value in the era of minimal residual disease (MRD) testing.MethodsHere, we used 4-colour mult
Externí odkaz:
https://doaj.org/article/392d740cfca04df7beab13da2e72ab62
Autor:
Roberto J. Pessoa de Magalhães, María-Belén Vidriales, Bruno Paiva, Carlos Fernandez-Gimenez, Ramón García-Sanz, Maria-Victoria Mateos, Norma C. Gutierrez, Quentin Lecrevisse, Juan F Blanco, Jose Hernández, Natalia de las Heras, Joaquin Martinez-Lopez, Monica Roig, Elaine Sobral Costa, Enrique M. Ocio, Martin Perez-Andres, Angelo Maiolino, Marcio Nucci, Javier De La Rubia, Juan-Jose Lahuerta, Jesús F. San-Miguel, Alberto Orfao
Publikováno v:
Haematologica, Vol 98, Iss 1 (2013)
Multiple myeloma remains largely incurable. However, a few patients experience more than 10 years of relapse-free survival and can be considered as operationally cured. Interestingly, long-term disease control in multiple myeloma is not restricted to
Externí odkaz:
https://doaj.org/article/a13769a907594d8e8d94633ae7e3a04a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Laura Notarfranchi, Anastasiia Zherniakova, Marta Lasa, Noemi Puig, María Teresa Cedena, Joaquin Martinez-Lopez, María José Calasanz, Diego Alignani, Leire Burgos, Irene Manrique, Yi-Ju Huang, Jochen Fracowiak, Clara Gomez, Felipe De Arriba, Paula Rodríguez-Otero, Luis Palomera, Anna Sureda, Maria Esther Clavero Sanchez, Miguel Angel Alvarez, Angela Ibanez Garcia, Miguel-Teodoro Hernández, Albert Perez, Ana Pilar Gonzalez, Enrique M. Ocio, Juan Flores-Montero, Alberto Orfao, Juan Jose Lahuerta, María-Victoria Mateos, Laura Rosiñol, Joan Bladé Creixenti, Jesús San-Miguel, Bruno Paiva
Publikováno v:
Blood. 140:2095-2097
Autor:
Juan-Jose Garcés, Maria-Teresa Cedena, Noemi Puig, Leire Burgos, Jose J. Perez, Lourdes Cordon, Juan Flores-Montero, Luzalba Sanoja-Flores, Maria-Jose Calasanz, Albert Ortiol, María-Jesús Blanchard, Rafael Rios, Jesus Martin, Rafael Martínez-Martinez, Joan Bargay, Anna Sureda, Javier de la Rubia, Miguel-Teodoro Hernandez, Paula Rodriguez-Otero, Javier de la Cruz, Alberto Orfao, Maria-Victoria Mateos, Joaquin Martinez-Lopez, Juan-Jose Lahuerta, Laura Rosiñol, Joan Blade, Jesus F. San-Miguel, Bruno Paiva
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
[Purpose]: Patients with multiple myeloma (MM) may show patchy bone marrow (BM) infiltration and extramedullary disease. Notwithstanding, quantification of plasma cells (PCs) continues to be performed in BM since the clinical translation of circulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f61a3bb97aeaa7ad1f365a2d7df9d571
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16523
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16523
Autor:
Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, Robin Carson, Pieter Sonneveld, Adrian Alegre Amor, Angelo Belotti, Lotfi Benboubker, Britta Besemer, Sevgi Besisik, Michele Cavo, Javier De La Rubia Comos, Meletios A. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Facon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hajek, Guner Hayri Ozsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Stefan Knop, Marie-Christine Kyrtsonis, Juan Jose Lahuerta, Xavier Leleu, Carmen Martinez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique Minnema, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlivan, Ludek Pour, Henk Th.J. Roerdink, Laura Rosinol Dacsh, Hans Salwender, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tulin Tuglular, Ali Unal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
APOLLO Trial Investigators 2021, ' Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 6, pp. 801-812 . https://doi.org/10.1016/S1470-2045(21)00128-5
LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
The Lancet. Oncology, 22(6), 801-812. Lancet Publishing Group
The Lancet Oncology, 22(6), 801-812. Lancet Publishing Group
instname
APOLLO Trial Investigators 2021, ' Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 6, pp. 801-812 . https://doi.org/10.1016/S1470-2045(21)00128-5
LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
The Lancet. Oncology, 22(6), 801-812. Lancet Publishing Group
The Lancet Oncology, 22(6), 801-812. Lancet Publishing Group
Background: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c27bb717191298826d5623e5b11470
http://hdl.handle.net/10261/261314
http://hdl.handle.net/10261/261314
Autor:
Noemí Puig, Cristina Agulló, Teresa Contreras, José-Juan Pérez, Irene Aires, María-José Calasanz, Ramón García-Sanz, Sergio Castro, Joaquín Martínez-López, Paula Rodríguez-Otero, Verónica González-Calle, Marta S González, Albert Oriol, Norma C Gutiérrez, Rafael Ríos-Tamayo, Laura Rosiñol, Miguel-Ángel Álvarez, Joan Bargay, Ana-Pilar González-Rodríguez, Adrián Alegre, Fernando Escalante, María-Belén Iñigo, Javier de la Rubia, Ana-Isabel Teruel, Felipe de Arriba, Luis Palomera, Miguel T Hernández, Javier López-Jiménez, Marta Reinoso, Aránzazu García-Mateo, Enrique M Ocio, Joan Bladé, Juan-José Lahuerta, María-Teresa Cedena, Bruno Paiva, Jesús F San Miguel, María-Victoria Mateos
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have therefore
Externí odkaz:
https://doaj.org/article/c81a444b8f6e434cb89c96b45ea2aec6
Autor:
Rodriguez-Otero, Paula, Gonzalez-Calle, Veronica, Calasanz, Maria-Jose, Cedena, Teresa, Puig, Noemi, Martinez-Lopez, Joaquín, Rosinol, Laura, Garcia, Miguel Teodoro Hernandez, Teruel, Ana Isabel, Gironella, Mercedes, Oriol, Albert, de la Rubia, Javier, Gonzalez-Rodriguez, Ana Pilar, Bargay, Joan, de la Fuente, Felipe de Arriba, Palomera, Luis, Gonzalez-Perez, Marta-Sonia, Balari, Anna Sureda, Palacios, Juan José Lahuerta, Bladé, Joan, San-Miguel, Jesús, Mateos, Maria-Victoria, Gutierrez, Norma
Publikováno v:
In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 2:S241-S242
Autor:
Rodriguez-Otero, Paula, Mateos, Maria-Victoria, Palacios, Juan José Lahuerta, Bladé, Joan, Heuck, Christoph, Kobos, Rachel, Albrecht, Claire, Doyle, Margaret, Gray, Kathleen, San-Miguel, Jesús
Publikováno v:
In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 2:S59-S60